U.K’s NICE To Help Build India’s Health Technology Assessment Board
This article was originally published in PharmAsia News
Executive Summary
India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.
You may also be interested in...
NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis
NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.
Erbitux and Avastin Aren’t Cost Effective, NICE Finds
Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.